Company intelligence / Profile preview
Cantab Pharmaceuticals
Cambridge, England, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
As of 2013, Cantab Biopharmaceuticals was advancing novel antibiotics (polymyxin derivatives) for multidrug-resistant infections and developing biosuperior biologics, with public funding and strategic partnerships supporting candidate optimization and preclinical work; specific clinical results not publicly available
- Therapeutic areas
- HematologyInfectious Diseases
- Modalities
- BiologicPeptidesProteinSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Selcia Limited (medicinal chemistry collaboration for anti-infectives program)Biomedical Catalyst Fund (UK government support/budget)
Beyond the preview
Go deeper on Cantab Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cantab Pharmaceuticals.